Divalproex Sodium and Topiramate for Migraine ProphylaxisMigren
| dc.contributor.author | Degirmenci, Yildiz | |
| dc.contributor.author | Karagoz, Erkan Taner | |
| dc.contributor.author | Karaman, Handan Isin Ozisik | |
| dc.date.accessioned | 2025-01-27T21:21:13Z | |
| dc.date.available | 2025-01-27T21:21:13Z | |
| dc.date.issued | 2012 | |
| dc.department | Çanakkale Onsekiz Mart Üniversitesi | |
| dc.description.abstract | Aim: To compare the efficacy, safety of topiramate and extended-release divalproex sodium in migraine prophylaxis. Material and Method: Study groups consisted of 22 patients with chronic migraine, randomly administered 1000mg extended-release divalproex sodium (first group), 21 patients given 100mg topiramate (second group).Study was 28-week randomized, prospectivetrial including 4-week baseline, 4-week titration, 20-week maintenancephase.Primary efficacy measure was reduction from baseline in 4-weekmigraine frequency.Secondary efficacy measures included responder rates,mean reduction in migraine duration,severity.Severity of headache wasquantified by using 10-point visual analogue scale (VAS). Responder rateswere defined as percentage of patients who demonstrated = 50%. reductionin migraine frequency per month. Results: Reduction from baseline migrainefrequency at the end of six month was primary outcome measure.Meanmigraine frequency at the end of study was 1.27 +/- 1 (baseline; mean +/- SD:3.6 +/- 2) in the first, 1.2 +/- 1.2 (baseline; mean +/- SD: 3.5 +/- 2.3) (p<0.0001) inthe second gr nt in frequency was observed in 16 patients (72.7%) in the first group, and 16 patients (76.2%) in the second group.Only a limited number of patients were excluded from the study due to side effects as 2 patients from the first group and 1 patient from the second group.The most common side effect was weight gain in the first and paresthesia in the second group. Discussion: Both divalproex sodium, topiramate were almost equally effective in reducing migraine frequency, duration, severity.Total relief from migraine attacks were more in topiramate than extended-release divalproex sodium. | |
| dc.identifier.doi | 10.4328/JCAM.724 | |
| dc.identifier.endpage | 307 | |
| dc.identifier.issn | 1309-0720 | |
| dc.identifier.issn | 1309-2014 | |
| dc.identifier.issue | 3 | |
| dc.identifier.startpage | 303 | |
| dc.identifier.uri | https://doi.org/10.4328/JCAM.724 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12428/28845 | |
| dc.identifier.volume | 3 | |
| dc.identifier.wos | WOS:000215547400015 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.publisher | Derman Medical Publ | |
| dc.relation.ispartof | Journal of Clinical and Analytical Medicine | |
| dc.relation.publicationcategory | info:eu-repo/semantics/openAccess | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WoS_20250125 | |
| dc.subject | Extended-Release Divalproex Sodium | |
| dc.subject | Topiramate | |
| dc.subject | Migraine Prophylaxis | |
| dc.title | Divalproex Sodium and Topiramate for Migraine ProphylaxisMigren | |
| dc.type | Article |
